...
首页> 外文期刊>Molecular genetics and metabolism >Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats.
【24h】

Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats.

机译:胰岛素可降低人型I型糖尿病患者和链脲佐菌素糖尿病大鼠的血清糖基磷脂酰肌醇磷脂酶D水平。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The enzyme glycosylphosphatidylinositol phospholipase D has a postulated role in the insulin-mimetic signaling pathway of glycosylphosphatidylinositol compounds. We have investigated enzyme activity in the serum of human type I diabetic patients and plasma and tissues of streptozotocin-induced diabetic rats following insulin administration. In the human diabetic patients serum enzyme activity fell by an average of 10.6% (SEM = 2.7; P = 0.008; n = 20) following administration of insulin. In addition serum enzyme activity appeared to be depleted by 27% (SEM = 8.8; P = 0.011; n = 10) compared to nondiabetic controls. In untreated diabetic rats plasma enzyme activity gradually increased 0.3-fold over a 6-week period (P < 0.001; n = 8), this increase was reversed and activity normalized when these animals were treated with insulin. Cloning of the rat glycosylphosphatidylinositol phospholipase D cDNA enabled confirmation of the liver as the principal organ of synthesis. Analysis of mRNA levels in the livers of the diabetic rats showed that gene expression was reduced in the insulin-treated animals compared to the noninsulin-treated controls by 0.7-fold (P = 0.004; n = 4). Tissue enzyme activity was also reduced in the insulin-treated rats; in skeletal muscle enzyme activity was 0.3-fold lower (P = 0.001; n = 4). Insulin therefore decreases glycosylphosphatidylinositol phospholipase D synthesis in diabetic animals resulting in decreased serum enzyme levels, suggesting a relationship between this enzyme and the function of insulin.
机译:糖基磷脂酰肌醇磷脂酶D在糖基磷脂酰肌醇化合物的胰岛素模拟信号通路中具有假定的作用。我们已经研究了人类I型糖尿病患者的血清以及链脲佐菌素诱导的糖尿病大鼠血浆和组织中胰岛素给药后的酶活性。在人类糖尿病患者中,服用胰岛素后,血清酶活性平均下降了10.6%(SEM = 2.7; P = 0.008; n = 20)。此外,与非糖尿病对照组相比,血清酶活性似乎减少了27%(SEM = 8.8; P = 0.011; n = 10)。在未经治疗的糖尿病大鼠中,血浆酶活性在6周内逐渐增加了0.3倍(P <0.001; n = 8),当这些动物接受胰岛素治疗后,这种增加被逆转并且活性恢复正常。大鼠糖基磷脂酰肌醇磷脂酶D cDNA的克隆使得能够确认肝脏是合成的主要器官。糖尿病大鼠肝脏中mRNA水平的分析表明,与未胰岛素治疗的对照组相比,胰岛素治疗的动物中的基因表达降低了0.7倍(P = 0.004; n = 4)。在胰岛素治疗的大鼠中,组织酶的活性也降低了。骨骼肌中酶的活性降低了0.3倍(P = 0.001; n = 4)。因此,胰岛素减少了糖尿病动物中糖基磷脂酰肌醇糖脂磷脂酶D的合成,导致血清酶水平降低,提示该酶与胰岛素功能之间存在关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号